News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
Editorial Board
For Authors
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice Between the LinesContemporary ConceptsJournalOncViewPodcastsReadout 360Insights from Experts at Mayo Clinic on Translating Evidence to Clinical PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid LeukemiaBrain CancerBreast CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
Editorial Board
For Authors
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Melanoma
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

IOM Finds No Link Between Silicone Implants and Cancer

August 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 8
Volume 8
Issue 8

WASHINGTON-An extensive review of the medical literature finds that women with silicone breast implants are no more likely to develop cancer and several other major ailments than women in the general population. The new report by the Institute of Medicine (IOM) concludes, however, that implants commonly lead to often-painful complications that may require surgery or other treatment.

WASHINGTON—An extensive review of the medical literature finds that women with silicone breast implants are no more likely to develop cancer and several other major ailments than women in the general population. The new report by the Institute of Medicine (IOM) concludes, however, that implants commonly lead to often-painful complications that may require surgery or other treatment.

“Based on all the evidence, we determined that the primary safety concern associated with breast implants is local complications resulting in pain, disfigurement, infections, and other medical problems,” said Stuart Bondurant, MD, who chaired the committee that prepared the report. “We could find no definite evidence linking breast implants to cancer, immunologic diseases, neurologic problems, or other systemic diseases.”

The Department of Health and Human Services funded the report, “Safety of Silicone Breast Implants,” as directed by Congress.

To complete its report, the committee evaluated more than 3,000 publications, including some 2,000 peer-reviewed articles. It is the third by a scientific panel to conclude that current evidence does not support a causal link between silicone breast implants and serious diseases such as cancer. The others were done by the UK’s Independent Review Group, released in 1998, and the National Science Panel, appointed by federal judge Sam C. Pointer, Jr., who is handling the lawsuits against implant makers that have been consolidated by the federal courts.

The issue of breast implants has been a contentious and controversial one for years. “The IOM excluded anyone from its committee who had participated in studies of breast implants, whose associations or prior statements might bias the results, who was involved with implant makers or relevant ongoing legal matters, or who had conflicts of interest,” said Dr. Bondurant, professor of medicine and dean emeritus of the University of North Carolina School of Medicine.

Problems With Mammograms

The IOM panel cautioned that implants can make it harder to detect breast cancer on mammograms “by obscuring a variable part of the breast tissue, distorting breast architecture, and especially in the presence of firm contractures, making a proper examination with proper compression of the breast more difficult and occasionally impossible.”

The committee also concluded that there is no evidence that mothers with implants pass on silicone to their infants when breast-feeding. Indeed, the panel noted, higher levels of silicon, the parent element of silicone, have been detected in cows’ milk and commercial baby formula than in the milk of nursing mothers with implants.

As for the relatively common local complications, such as implant rupture, contraction, and deflation, the panel found it difficult “to come up with a precise estimate of the frequencies of these outcomes in the absence of large, long-term, systematic follow-up studies,” said vice chair Virginia L. Ernster, PhD, of the University of California, San Francisco.

In its section on cancer, the panel concluded that the available evidence fails to support an association of silicone or silicone breast implants with experimental carcinogenesis (other than rodent solid-state carcinogenesis), primary, or recurrent breast cancer, breast sarcoma, or other solid tumors, lymphoma, or myeloma.

“If anything, evidence (though limited) suggests a lower risk of breast cancer in women with silicone breast implants,” the report said. At a press conference, Dr. Bondurant hastened to emphasize that the report did not mean to imply any protective effect of silicone implants.

The panel’s review also failed to substantiate reported links between implants and a recurrence of breast cancer or an association with increased risk of sarcomas, monoclonal gammopathy of undetermined significance, and immunoglobulin G myeloma.

Articles in this issue

False positives frequent in CT lung cancer screening trial
Stereotactic Core Biopsy Establishes Many Prognostic Factors
Breast Cancer Prevention With Tamoxifen Appears Cost-Effective
NCI Discovers Gene Variations From Existing Databases
CPDR Unveils First Center Solely for Prostate Cancer Research
Going Beyond CHOP in Advanced Large-Cell Lymphoma
Memorial Sloan-Kettering Opens Rockefeller Outpatient Pavilion
Ernst Wynder, Pioneer in Preventive Medicine
AHCPR Plans Health Care Market, Managed Care Research Centers
NSAIDs May Protect Against Common GI Cancers
Four Researchers Receive General Motors Awards
Anal Condylomata More Threatening in HIV+ Patients
IOM Finds No Link Between Silicone Implants and Cancer
IL-12 Gene Therapy Inhibits Osteosarcoma Lung Mets in Mice
Law May Play an Important Role in End of Life Decisions
Related Videos
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
Experts on MM
A panel of 4 experts on multiple myeloma seated at a long table
Marwan G. Fakih, MD, an expert on colorectal cancer
Experts on MM
Related Content
Advertisement

EU's CHMP Recommends Subcutaneous Atezolizumab Approval in Multiple Cancers

EU's CHMP Recommends Subcutaneous Atezolizumab Approval in Multiple Cancers

November 28th 2023
Article

Data from the phase 1b/3 IMscin001 trial support the Committee for Medicinal Products for Human Use’s positive opinion on subcutaneous atezolizumab in lung cancer and other disease types.


Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.


Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.

Belantamab Mafodotin Improves PFS in Relapsed/Refractory Multiple Myeloma

November 28th 2023
Article

Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.


New treatment updates could help find more patient subtypes to target and treat in the world of CRC.

Multidisciplinary Care and New Treatment Options in CRC

November 20th 2023
Podcast

New treatment updates could help find more patient subtypes to target and treat in the world of CRC, according to Kristen K. Ciombor, MD, MSCI.


Safety data from the phase 3 PREVAPIX-ALL trial support the use of apixaban among pediatric patients with acute lymphoblastic leukemia who are at high risk of thrombosis.

Apixaban Yields No Significant Benefit in Acute Lymphoblastic Leukemia

November 27th 2023
Article

Safety data from the phase 3 PREVAPIX-ALL trial support the use of apixaban among pediatric patients with acute lymphoblastic leukemia who are at high risk of thrombosis.


Total costs for endometrial cancer therapy in the first line appear to be higher for those diagnosed with metastatic disease compared with those who do not have metastatic disease.

Frontline Advanced Endometrial Cancer Therapy Confers High Economic Burden

November 27th 2023
Article

Total costs for endometrial cancer therapy in the first line appear to be higher for those diagnosed with metastatic disease compared with those who do not have metastatic disease.

Related Content
Advertisement

EU's CHMP Recommends Subcutaneous Atezolizumab Approval in Multiple Cancers

EU's CHMP Recommends Subcutaneous Atezolizumab Approval in Multiple Cancers

November 28th 2023
Article

Data from the phase 1b/3 IMscin001 trial support the Committee for Medicinal Products for Human Use’s positive opinion on subcutaneous atezolizumab in lung cancer and other disease types.


Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.


Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.

Belantamab Mafodotin Improves PFS in Relapsed/Refractory Multiple Myeloma

November 28th 2023
Article

Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.


New treatment updates could help find more patient subtypes to target and treat in the world of CRC.

Multidisciplinary Care and New Treatment Options in CRC

November 20th 2023
Podcast

New treatment updates could help find more patient subtypes to target and treat in the world of CRC, according to Kristen K. Ciombor, MD, MSCI.


Safety data from the phase 3 PREVAPIX-ALL trial support the use of apixaban among pediatric patients with acute lymphoblastic leukemia who are at high risk of thrombosis.

Apixaban Yields No Significant Benefit in Acute Lymphoblastic Leukemia

November 27th 2023
Article

Safety data from the phase 3 PREVAPIX-ALL trial support the use of apixaban among pediatric patients with acute lymphoblastic leukemia who are at high risk of thrombosis.


Total costs for endometrial cancer therapy in the first line appear to be higher for those diagnosed with metastatic disease compared with those who do not have metastatic disease.

Frontline Advanced Endometrial Cancer Therapy Confers High Economic Burden

November 27th 2023
Article

Total costs for endometrial cancer therapy in the first line appear to be higher for those diagnosed with metastatic disease compared with those who do not have metastatic disease.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.